UPDATED: Biotech leaders call on industry to cut ties with Russia amid Ukraine invasion

By Kyle LaHucik,Annalee Armstrong,Max Bayer,Eric Sagonowsky,Kevin Dunleavy

CEOs at dozens of biotechs and investors from the industry's leading venture firms urged their global business counterparts to "disengage from Russian industry" over the weekend. 

read more

Sponsored: The Importance of the Patient in Advancing Care in Rare Diseases

Sponsored by: Ipsen

Read more to learn about Ipsen's commitment to the rare disease community and to ensuring their patients have a voice.

read more

Goldfinch's phase 2 kidney disease therapy scores in one indication, misses in another

By Max Bayer

Goldfinch Bio’s kidney disease treatment quelled rising protein levels in patients’ urine, but only in one of the two diseases being tested, according to initial data from a phase 2 trial.  

read more

FDA sticks a fork in Reata’s treatment for chronic kidney disease

By Max Bayer

The FDA rejected Reata Pharmaceuticals' treatment for chronic kidney disease, a final blow to the company's lead indication for the drug.

read more

Amryt's shares tumble as FDA stiff-arms skin treatment, a month after EU delay revealed

By Annalee Armstrong

Amryt can’t catch a break. The U.K. biotech’s shares were sent into the red as the FDA returned a complete response letter for the rare skin disease therapy Oleogel-S10.

read more

Blueprint marks protein degrader path in $632M biobucks pact with a Vant

By Kyle LaHucik

Blueprint Medicines dives into the protein degradation space in a $632 million biobucks deal with Roivant Sciences' Proteovant Therapeutics. The collaboration initially revolves around two targets, but the deal could double in size if the partners opt into two more.

read more

Huadong buys into Heidelberg, signs nearly $1B deal to gain access to four cancer assets

By Kyle LaHucik

Huadong Medicine will invest about $118 million for a 35% stake in Heidelberg Pharma plus dole out up to $930 million in a licensing deal for four oncology assets.

read more

After raking in billions with its COVID shot, Moderna faces patent infringement suit related to vaccine delivery tech

By Fraiser Kansteiner

Last last year, Moderna lost a legal bid to invalidate two Arbutus Biopharma patents tied to the delivery of its COVID-19 vaccine. At the time, it wasn’t so much a question of whether Arbutus would sue the mRNA vaccine giant for infringement, but when. Now, the other shoe has dropped. 

read more

Masimo’s brain-monitoring headset nabs FDA nod for use in kids

By Andrea Park

The SedLine system was originally cleared by the FDA in 2004, with the agency’s permission to monitor brain activity while adult patients are under anesthesia.

read more

Bristol Myers' Opdivo steps in FDA fast lane for potential first-in-class nod in pre-surgery lung cancer

By Angus Liu

As immuno-oncology agents gradually move in to treat earlier stages of diseases, Bristol Myers Squibb has earned a regulatory boost that could potentially make it the first company to enter a key lung cancer setting.

read more

Handheld ultrasound developer Butterfly Network stretches wings to 35% annual sales growth

By Conor Hale

With point-of-care ultrasound probes and subscription plans, the company raked in $62.6 million in 2021 compared to 2020's $46.3 million.

read more

Cerner's 2021 revenue reaches $5.77B as pending Oracle acquisition draws pension fund lawsuit

By Heather Landi

Two months after Oracle announced plans to buy Cerner, the health IT company is now being sued by a pension fund over concerns that the company's leadership "stymied potential bidders" while pushing forward a deal with Oracle and didn't explore other alternatives.

read more

Whitepaper: Versatility of Softgel Technology - Encapsulation of a Volatile Compound

Sponsored by: Catalent

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

Whitepaper: The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

Sponsored by: Catalent

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Whitepaper: The CNS Market: 2021 Year in Review & Outlook for 2022

Sponsored by: Blue Matter

What’s in store for the CNS therapeutics market in 2022? This paper looks ahead in Alzheimer’s, Parkinson’s, DMD, psychiatric disorders, pain, and more.

Webinar: The Faster Path From Pre-Filled Syringe to Auto-Injector

Sponsored by: Catalent Biologics

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Whitepaper: Formulation Strategies When Transitioning From Vial to PFS

Sponsored by: Catalent Biologics

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.